Aridis Awarded Two Grants Totaling over $2M by the NIH, BARDA, and RCE to Develop Formulation Technologies for Biodefense
San Jose, CA September 28th, 2008

Aridis Pharmaceuticals, LLC announced today that it had received two additional grant awards totaling more than $2 million from the NIH and the Biomedical Advanced Research and Development Authority (BARDA) and the Mid Atlantic Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE). The first award, from the NIH's National Institute of Allergy and Infectious Diseases (NIAID), is part of a $22M contract shared with Integrated Biotherapeutics (IBT) for the development of formulations for IBT's filovirus vaccine candidates desiged to protect against Ebola and Marburg viruses (more..). Tthe second award from RCE is in collaboration with the laboratories of Drs. Eileen Barry and Myron Levine will be used to develop stabilization technology for Franciscella tularensis vaccines.

Dr. Vu Truong, Aridis’ co-founder and Chief Technology Officer of Aridis stated that “These awards are gratifying and further validate the broad reach of our formulation technologies”. "Aridis' scientific experts will diligently apply their unique know-how and strong formulation expertise to futher advance the development of these important biodefense vaccines ".

About Aridis
Aridis is a privately held biotechnology company applying proprietary stabilization formulation and drug delivery technologies to produce novel monoclonal antibodies and vaccines to treat infectious diseases. Aridis’ new generation of stabilized vaccines and protein therapeutics are cost-effective and convenient to administer in “ready-to-use” oral and inhalational delivery formats. Aridis’ product pipeline includes PanaecinTM, a small molecule anti-infetive compound with broad activities against bacteria, viruses, and fungi, AerucinTM, a monoclonal antibody against Pseudomonas aeruginosa initially being developed to treat chronic lung infections in cystic fibrosis patients and RotavaxTM, a live attenuated oral rotavirus vaccine to prevent infant diarrhea. Additional product candidates in preclinical development include an oral vaccine to prevent traveler’s diarrhea due to shigella infections and an oral anthrax vaccine to protect against live anthrax spore exposure.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of RotavaxTM, AerucinTM, Aridis proprietary formulation and delivery technologies, about Aridis’ strategy, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Aridis’ expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Aridis’ research and clinical studies and its ability to obtain additional financing. These forward-looking statements represent Aridis’ judgment as of the date of this release. Aridis disclaims any intent or obligation to update these forward-looking statements.

For more information, please contact:

Eric Patzer
President of Aridis
408-385-1742.
Source: Aridis, LLC.